drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (ADC)
drug_description
Anti-HER2 antibody–drug conjugate delivering the microtubule inhibitor MMAE to HER2 (ERBB2)-expressing tumor cells, leading to internalization and microtubule disruption.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Disitamab vedotin is an anti-HER2 (ERBB2) antibody–drug conjugate that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor MMAE via a cleavable linker. Released MMAE disrupts tubulin polymerization, causing G2/M arrest and apoptosis, with potential bystander killing of adjacent tumor cells.
drug_name
Disitamab vedotin (RC48)
nct_id_drug_ref
NCT05578287